Epstein-Barr_JJ
virus_NN
EBNA3C_NN
represses_VBZ
Cp_NN
,_,
the_DT
major_JJ
promoter_NN
for_IN
EBNA_NN
expression_NN
,_,
but_CC
has_VBZ
no_DT
effect_NN
on_IN
the_DT
promoter_NN
of_IN
the_DT
cell_NN
gene_NN
CD21_NN
._.

EBNA3C_NN
is_VBZ
a_DT
potent_JJ
repressor_NN
of_IN
transcription_NN
when_WRB
bound_VBN
to_TO
DNA_NN
as_IN
a_DT
fusion_NN
with_IN
the_DT
DNA_NN
binding_NN
domain_NN
-LRB-_-LRB-
DBD_NN
-RRB-_-RRB-
of_IN
GALA_NN
._.

A_DT
survey_NN
of_IN
promoters_NNS
has_VBZ
revealed_VBN
that_IN
the_DT
wild-type_JJ
,_,
unfused_JJ
EBNA3C_NN
can_MD
specifically_RB
repress_VB
expression_NN
from_IN
reporter_NN
plasmids_NNS
containing_VBG
the_DT
Epstein-Barr_JJ
virus_NN
Cp_NN
latency-associated_JJ
promoter_NN
._.

Repression_NN
of_IN
Cp_NN
activity_NN
required_VBD
amino_NN
acids_NNS
207_CD
to_TO
368_CD
,_,
which_WDT
encompasses_VBZ
a_DT
region_NN
resembling_VBG
a_DT
basic_JJ
DBD_NN
adjacent_JJ
to_TO
a_DT
leucine_NN
zipper_NN
DNA_NN
binding_NN
motif_NN
and_CC
a_DT
site_NN
which_WDT
binds_VBZ
to_TO
the_DT
cellular_JJ
factor_NN
CBF1\/RBP-Jkappa_NN
._.

However_RB
,_,
amino_NN
acids_NNS
207_CD
to_TO
368_CD
are_VBP
dispensable_JJ
when_WRB
the_DT
protein_NN
is_VBZ
bound_VBN
to_TO
DNA_NN
as_IN
a_DT
fusion_NN
with_IN
the_DT
GAL4_NN
DBD_NN
,_,
thus_RB
implicating_VBG
this_DT
region_NN
in_IN
DNA_NN
binding_NN
._.

Mutation_NN
of_IN
the_DT
CBF1\/RBP-Jkappa_NN
binding_NN
site_NN
in_IN
EBNA3C_NN
abrogated_VBD
repression_NN
,_,
strongly_RB
suggesting_VBG
that_IN
CBF1\/RBP-Jkappa_NN
is_VBZ
necessary_JJ
for_IN
targeting_VBG
the_DT
viral_JJ
protein_NN
to_TO
Cp_NN
._.

Consistent_JJ
with_IN
this_DT
result_NN
,_,
mutation_NN
of_IN
the_DT
EBNA2_NN
response_NN
element_NN
-LRB-_-LRB-
a_DT
CBF1\/RBP-Jkappa_NN
binding_NN
site_NN
-RRB-_-RRB-
in_IN
Cp_NN
also_RB
prevented_VBD
significant_JJ
repression_NN
._.

In_IN
addition_NN
,_,
amino_NN
acids_NNS
346_CD
to_TO
543_CD
,_,
which_WDT
were_VBD
previously_RB
defined_VBN
as_IN
important_JJ
for_IN
the_DT
repressor_NN
activity_NN
of_IN
the_DT
GAL4-EBNA3C_NN
fusion_NN
proteins_NNS
,_,
also_RB
appear_VBP
to_TO
be_VB
necessary_JJ
for_IN
the_DT
repression_NN
of_IN
Cp_NN
._.

Since_IN
repression_NN
by_IN
these_DT
fusions_NNS
was_VBD
not_RB
observed_VBN
in_IN
all_DT
cell_NN
types_NNS
,_,
it_PRP
seems_VBZ
likely_JJ
that_IN
EBNA3C_NN
either_CC
depends_VBZ
on_IN
a_DT
corepressor_NN
which_WDT
may_MD
interact_VB
with_IN
amino_NN
acids_NNS
346_CD
to_TO
543_CD
or_CC
is_VBZ
modified_VBN
in_IN
a_DT
cell-specific_JJ
manner_NN
in_IN
order_NN
to_TO
repress_VB
._.

These_DT
data_NNS
are_VBP
consistent_JJ
with_IN
EBNA3C_NN
contributing_VBG
to_TO
the_DT
regulation_NN
of_IN
EBNA_NN
expression_NN
in_IN
latently_RB
infected_VBN
B_NN
cells_NNS
through_IN
CBF1\/RBP-Jkappa_NN
and_CC
another_DT
factor_NN
,_,
but_CC
this_DT
need_VBP
not_RB
directly_RB
involve_VB
EBNA2_NN
._.

Finally_RB
,_,
although_IN
it_PRP
has_VBZ
been_VBN
reported_VBN
that_IN
EBNA3C_NN
can_MD
upregulate_VB
CD21_NN
in_IN
some_DT
B_NN
cells_NNS
,_,
we_PRP
were_VBD
unable_JJ
to_TO
demonstrate_VB
any_DT
effect_NN
of_IN
EBNA3C_NN
on_IN
reporter_NN
plasmids_NNS
which_WDT
contain_VBP
the_DT
CD21_NN
promoter_NN
._.

